
Cogent Biosciences Investor Relations Material
Latest events

Study Update
Cogent Biosciences

Q1 2025
6 May, 2025

Q4 2024
25 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cogent Biosciences Inc
Access all reports
Cogent Biosciences Inc. is a biotechnology company focused on the development of precision therapies for genetically defined diseases. The company's lead product, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor targeting mutations in the KIT receptor tyrosine kinase. These mutations are critical in conditions such as systemic mastocytosis and advanced gastrointestinal stromal tumors. Cogent Biosciences holds a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Key slides for Cogent Biosciences Inc


The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024
Cogent Biosciences Inc


Jefferies Global Healthcare Conference 2025
Cogent Biosciences Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
COGT
Country
🇺🇸 United States